SCHEMBL2265930

SCHEMBL2265930

OB(O)c1cccc(Cl)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
CYP3A4 P08684 1/20 0.41
ALDH1A1 P00352 6/20 0.36
GAA P10253 5/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
AGTR1 P30556 1/20 0.34
HTR3E A5X5Y0 3/20 0.33
HTR3B O95264 3/20 0.33
HTR3A P46098 3/20 0.33
HTR3D Q70Z44 3/20 0.33
HTR3C Q8WXA8 3/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GRM5 P41594 1/20 0.33
ENPP2 Q13822 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
EGFR P00533 1/20 0.32
ERBB3 P21860 1/20 0.32
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20067383 0.82 ENPP2 (0.36) TSHRALDH1A1ENPP2TDP1ALOX15
SCHEMBL31139482 0.75 CCR1 (0.40) ALDH1A1MAPTHPGDSMN1; SMN2ENPP2
Hydrogen Peroxide SCHEMBL15167446 0.73 TSHR (0.52) TSHRCYP3A4ALDH1A1GAAMAPT
SCHEMBL29956196 0.73 ENPP2 (0.34) ALDH1A1MAPTHPGDENPP2
SCHEMBL58195 0.73
SCHEMBL31138329 0.71 MAPT (0.32) MAPT
SCHEMBL28356239 0.71 NOS2 (0.44) ALDH1A1ENPP2
SCHEMBL313923 0.71 HTR7 (0.35) TSHRALDH1A1HPGDGRM5
SCHEMBL29955389 0.71 CCR1 (0.48) TSHRCYP3A4ALDH1A1HPGDHTR3E
SCHEMBL956317 0.71 CCR1 (0.48) TSHRCYP3A4ALDH1A1HPGDHTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421225-B2 Heteroaromatic amide derivative and medicament containing the same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2025-09-23 US disclosed
CN-113943289-B Organic compound, application thereof and organic electroluminescent device 北京鼎材科技有限公司 2025-01-28 CN disclosed
US-12116369-B2 Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators Bial—R&D Investments, S.A. (PT) 2024-10-15 US disclosed
CN-115232153-B Organic compound containing naphthalene and 1, 10-phenanthroline structure and OLED light-emitting device containing organic compound 江苏三月科技股份有限公司 2024-07-16 CN disclosed
EP-3851436-B1 NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2024-06-12 EP disclosed
CN-118103369-A Pyridolactam derivatives, preparation method and application thereof 浙江海正药业股份有限公司 2024-05-28 CN disclosed
US-20230098494-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. 2023-03-30 US disclosed
US-20230086366-A1 Novel heteroaromatic amide derivative and medicament containing the same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2023-03-23 US disclosed
WO-2023030478-A1 PYRIDOLACTAM DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 浙江海正药业股份有限公司 2023-03-09 WO disclosed
WO-2023030478-A1 PYRIDOLACTAM DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 浙江海正药业股份有限公司 2023-03-09 WO disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
US-20100240678-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2010-09-23 US disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed
US-20090253684-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2009-10-08 US disclosed
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2009-09-10 US disclosed
US-7504513-B2 Thiazolyl-benzimidazoles HOFFMAN-LA ROCHE INC. (US) 2009-03-17 US disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
US-20090054466-A1 Leukotriene B4 Inhibitors DOMINIQUE ROMYR 2009-02-26 US disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed
US-20070203210-A1 Thiazolyl-benzimidazoles BOYLAN JOHN FREDERICK 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12116369-B2 Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators GBA1, GALC, GBA3 TSHR 3417/4885CYP3A4 2074/4885ALDH1A1 1260/4885
US-20090253684-A1 LEUKOTRIENE B4 INHIBITORS LTB4R2, LTB4R, LTC4S TSHR 2650/4885CYP3A4 406/4885ALDH1A1 697/4885
US-20070203210-A1 Thiazolyl-benzimidazoles CYP3A7, CYP2C19, CYP3A5 TSHR 876/4885CYP3A4 6/4885ALDH1A1 100/4885
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS LTB4R2, LTB4R, LTC4S TSHR 2676/4885CYP3A4 402/4885ALDH1A1 685/4885
US-20090054466-A1 Leukotriene B4 Inhibitors LTB4R2, LTB4R, LTC4S TSHR 2676/4885CYP3A4 402/4885ALDH1A1 685/4885
US-20230098494-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 TSHR 3052/4885CYP3A4 1579/4885ALDH1A1 1104/4885
US-20230086366-A1 Novel heteroaromatic amide derivative and medicament containing the same SCN7A, HCN4, SCN4A TSHR 639/4885CYP3A4 338/4885ALDH1A1 1627/4885
US-20100240678-A1 LEUKOTRIENE B4 INHIBITORS LTB4R2, LTB4R, LTC4S TSHR 2676/4885CYP3A4 402/4885ALDH1A1 685/4885
US-12421225-B2 Heteroaromatic amide derivative and medicament containing the same SCN7A, HCN4, SCN4A TSHR 556/4885CYP3A4 286/4885ALDH1A1 1596/4885
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA TSHR 1753/4885CYP3A4 1613/4885ALDH1A1 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.